Start exploring your own markets for free

🚀 Try for Free

AI Therapeutics

Light Search completed
Invite
Radar Tracking

Subspaces (4)

Drug Discovery Optimization
Biomarker Identification
Genomic Data Analysis
Drug Repurposing

Pending to review

Not sure yet

Interested

Not interested

Download list

Showing 104 results
Company
Fit assessment
Description
Subspaces
Tags
HQ Location
Founding Date
Employees
Total Funding Raised
Last Funding Event
Received on
Cellkey

The company effectively leverages machine learning for glycopeptide analysis, enabling pattern discovery and expanding therapeutics while focusing on biomarker identification.

Developer of AI-based integrated glycopeptide analysis platform intended to develop biotechnologies that contribute towards prolonging human lives. The company utilizes artificial intelligence and machine learning to diagnose and treat life-threatening diseases by combining unique glycoprotein analysis, helping health workers to predict various diseases and qualitatively and quantitatively analyze the type and location of glycoprotein.
  • Biomarker Identification
Light Search
South Korea201911 - 50Seed, February 28, 2022
Oct 14, 2024
Ariana Pharma

Ariana Pharma effectively leverages machine learning and advanced analytics to discover patterns, expand therapeutics, and identify biomarkers, enhancing drug development processes.

Developer of biomarker data insights and diagnostic testing technology designed to accelerate drug discovery and development. The company's technology provides Knowledge Management and Extraction (KEM), a decision support system for testing and providing insights on multi-parametric and multi-objective data, enabling clients to access intelligent data insights and consultancy to go beyond conventional statistics and enrich clinical processes.
  • Biomarker Identification
Light Search
Paris (France)200311 - 50$2.30MSeries A, $2.30M, July 9, 2008
Oct 14, 2024
silicosome

Silicosome leverages machine learning for drug design, discovers patterns in biological data, and develops new therapeutics, including biomarker identification.

  • Biomarker Identification
Light Search
United States11 - 50NA
Oct 14, 2024
Orikami

Orikami leverages machine learning and data analysis to develop digital biomarkers, enhancing therapeutic options and personalizing healthcare for chronic disease management.

Developer of medical-grade digital biomarker technology designed to make an impact in chronic disease areas. The company's technology uses an artificial intelligence-powered digital biomarker platform and speeds up the journey from biomarker discovery through validation to delivery at scale, enabling medical specialists to make decision support, treatment support, and patient coaching.
  • Biomarker Identification
Light Search
Netherlands201111 - 50$659.06KSeed, $659.06K, October 9, 2019
Oct 14, 2024